文献速递外周动脉疾病

血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂与慢性肢体威胁性缺血患者无截肢生存改善相关

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with improved amputation-free survival in chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2024-09-19

基于Vascular Quality Initiative的Vascular Implant Surveillance and Interventional Outcomes Network数据库,纳入34,284例接受外周血管介入的慢性肢体威胁性缺血患者,46.3%出院时使用ACEIs/ARBs。出院使用ACEIs/ARBs者1年无截肢生存率为70.5%,未使用者为59.5%(P < .001);校正混杂因素后,ACEIs/ARBs使用与较低的1年死亡(HR 0.77)、截肢(HR 0.89)及截肢或死亡(HR 0.79)独立相关。

要点

  • 接受外周血管介入的慢性肢体威胁性缺血患者中,46.3%出院时使用ACEIs/ARBs。
  • 出院使用ACEIs/ARBs者1年无截肢生存率70.5%,未使用者59.5%(P < .001)。
  • 校正混杂因素后,ACEIs/ARBs使用与较低的1年死亡、截肢及截肢或死亡独立相关。

核心结论

  • 在因慢性肢体威胁性缺血接受外周血管介入的患者中,ACEIs/ARBs使用与1年较低的截肢、改善的生存及无截肢生存独立相关。
  • 超过一半的患者出院时未使用这些药物,作者认为这构成了一个潜在的质量改进领域。

研究设计与样本

  • 基于Vascular Quality Initiative的Vascular Implant Surveillance and Interventional Outcomes Network数据库,纳入接受外周血管介入的患者。
  • 共纳入34,284例患者,其中46.3%出院时使用ACEIs/ARBs。
  • 主要结局为无截肢生存,采用Kaplan-Meier生存分析和多变量Cox回归分析评估1年结局。

主要发现

  • 出院使用ACEIs/ARBs者与未使用者相比,更可能为吸烟者、合并糖尿病和高血压,也更可能表现为静息痛。
  • 1年总生存率:ACEIs/ARBs组79.1% vs 未使用组69.4%(P < .001)。
  • 1年免于截肢率:ACEIs/ARBs组87.8% vs 未使用组84.2%(P < .001)。
  • 1年无截肢生存率:ACEIs/ARBs组70.5% vs 未使用组59.5%(P < .001)。
  • 校正潜在混杂因素后,ACEIs/ARBs使用与较低的1年死亡率(HR 0.77;95%CI 0.7-0.8;P < .001)、截肢率(HR 0.89;95%CI 0.8-0.9;P < .001)及截肢或死亡复合终点(HR 0.79;95%CI 0.76-0.8;P < .001)相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the Heart Outcomes Prevention Evaluation study, investigators found that ramipril was associated with improved survival as well as decreased MI and stroke rates in patients with peripheral arterial disease. Nonetheless, their effect on chronic limb-threatening ischemia (CLTI)-specific outcomes is unclear. We aim to assess the effect of ACEIs/ARBs on amputation-free survival in patients with CLTI undergoing peripheral vascular intervention (PVI) in a Medicare-linked database. METHODS: Patients undergoing PVI in the Vascular Quality Initiative Vascular Implant Surveillance and Interventional Outcomes Network database were included. Primary outcomes included amputation-free survival. Kaplan-Meier survival and multivariable Cox regression analyses were used to assess 1-year outcomes. RESULTS: A total of 34,284 patients were included, 46.3% of whom were discharged on ACEIs/ARBs. Patients discharged on ACEIs/ARBs were more likely to be smokers, have diabetes, and have hypertension. They were also more likely to present with rest pain. The overall 1-year survival rate for patients on ACEIs/ARBs vs those who are not was (79.1% vs 69.4%; P < .001). Freedom from amputation was 87.8% for patients on ACEIs/ARBs vs 84.2% for those who were not (P < .001). Amputation-free survival was 70.5% vs 59.5% for ACEIs/ARBs vs no ACEIs/ARBs (P < .001). After adjusting for potential confounders, ACEIs/ARBs use was associated with lower 1-year mortality (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.7-0.8; P < .001), amputation (HR, 0.89; 95% CI, 0.8-0.9; P < .001), and amputation or death (HR, 0.79; 95% CI, 0.76-0.8; P < .001). CONCLUSIONS: ACEIs/ARBs were associated independently with lower amputation, improved survival, and amputation-free rates survival at 1 year in patients with CLTI undergoing PVI. The fact that more than one-half the patients were not discharged on these medications presents an area for potential quality improvement.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Elsayed N, Straus SL, Clouse D, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with improved amputation-free survival in chronic limb-threatening ischemia. J Vasc Surg. 2024. PMID: 39303862. doi:10.1016/j.jvs.2024.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。